Polly Niravath
The Methodist Hospital Research Institute · Houston Methodist Cancer Center · Baylor College of Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Polly Niravath as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:54 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05305924 · Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast CancerThe Methodist Hospital Research Institute · recruiting · ER-Positive Breast Cancer, HER2-negative Breast Cancer · principal investigator
- Ph2NCT03820141 · Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast CancerThe Methodist Hospital Research Institute · active not recruiting · Breast Cancer · principal investigator
- Ph1NCT03742245 · Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast CancerThe Methodist Hospital Research Institute · active not recruiting · Breast Cancer Metastatic, Breast Cancer · principal investigator
- Ph1/Ph2NCT02834403 · L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer PatientsThe Methodist Hospital Research Institute · completed · Metastatic Triple Negative Breast Cancer · principal investigator
- Ph2NCT01984138 · REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor TherapyPolly A. Niravath, MD · active not recruiting · Estrogen Receptor Positive Breast Cancer, Breast Cancer · principal investigator
- Ph2NCT01612728 · Treatment for Joint Pains Due to Aromatase Inhibitor Therapy in Breast CancerBaylor Breast Care Center · withdrawn · Breast Cancer, Arthralgia, Joint Pain · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:54 UTC. The ranking covers the 200 most relevant of 16 PubMed records, and a shared surname and initials can bring in a namesake. All 16 on PubMed
- TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.J Clin Oncol · 2019306 citationsRCR 11.1
- 177 citationsRCR 4.9
- Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.Clin Cancer Res · 2017167 citationsRCR 4.6
- 137 citationsRCR 4.3
- A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer.Sci Transl Med · 202196 citationsRCR 4.8
- A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study).Breast Cancer Res · 201957 citationsRCR 1.9
- TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.Clin Cancer Res · 202054 citationsRCR 1.8
- A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxanes in the Treatment of Patients With Advanced or Metastatic Anthracycline-refractory Breast Cancer.Clin Breast Cancer · 202149 citationsRCR 3.1
- A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer.Clin Cancer Res · 202234 citationsRCR 2.1
- Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy.Sci Rep · 202127 citationsRCR 1.5